MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma

• Status: Terminated
• Trial end date: 2017-02-17

Summary

The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Part 2 dose, safety and efficacy of MLN1117 (TAK-117) in combination with docetaxel, paclitaxel, investigational TAK-659 or investigational alisertib in adult participants with advanced and metastatic gastric or gastroesophageal adenocarcinoma. The study consists of a dose escalation phase (Part 1) and a dose expansion phase (Part 2).

• Phase: Phase 1

Details

• Lead Sponsor: Millennium Pharmaceuticals, Inc.
• Treatments: Albumin-Bound Paclitaxel; Antineoplastic Agents; Docetaxel; Paclitaxel; Serabelisib